HMOX1 upregulation promotes ferroptosis in diabetic atherosclerosis

Life Sci. 2021 Nov 1:284:119935. doi: 10.1016/j.lfs.2021.119935. Epub 2021 Sep 8.

Abstract

Objective: Atherosclerotic vascular disease remains the principal cause of death and disability among patients with type 2 diabetes. Unfortunately, the problem is not adequately resolved by therapeutic strategies with currently available drugs or approaches that solely focus on optimal glycemic control. To identify the key contributors and better understand the mechanism of diabetic atherosclerotic vascular disease, we aimed to elucidate the key genetic characteristics and pathological pathways in atherosclerotic vascular disease through nonbiased bioinformatics analysis and subsequent experimental demonstration and exploration in diabetic atherosclerotic vascular disease.

Methods and results: Sixty-eight upregulated and 23 downregulated genes were identified from the analysis of gene expression profiles (GSE30169 and GSE6584). A comprehensive bioinformatic assay further identified that ferroptosis, a new type of programmed cell death and HMOX1 (a gene that encodes heme oxygenase), were vital factors in atherosclerotic vascular disease. We further demonstrated that diabetes significantly increased ferroptosis and HMOX1 levels compared to normal controls. Importantly, the ferroptosis inhibitor ferrostatin-1 (Fer-1) effectively attenuated diabetic atherosclerosis, suggesting the causative role of ferroptosis in diabetic atherosclerosis development. At the cellular level, Fer-1 ameliorated high glucose high lipid-induced lipid peroxidation and downregulated ROS production. More importantly, HMOX1 knockdown attenuated Fe2+ overload, reduced iron content and ROS, and alleviated lipid peroxidation, which led to a reduction in ferroptosis in diabetic human endothelial cells.

Conclusions: We demonstrated that HMOX1 upregulation is responsible for the increased ferroptosis in diabetic atherosclerosis development, suggesting that HMOX1 may serve as a potential therapeutic or drug development target for diabetic atherosclerosis.

Keywords: Atherosclerosis; Computational biology; Diabetes mellitus; Ferroptosis; Heme oxygenase 1.

MeSH terms

  • Animals
  • Apolipoproteins E / deficiency
  • Apolipoproteins E / metabolism
  • Atherosclerosis / complications
  • Atherosclerosis / enzymology*
  • Atherosclerosis / genetics*
  • Atherosclerosis / pathology
  • Cyclohexylamines / pharmacology
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / enzymology*
  • Diabetes Mellitus, Experimental / genetics*
  • Diabetes Mellitus, Experimental / pathology
  • Diet, High-Fat
  • Disease Progression
  • Feeding Behavior
  • Female
  • Ferroptosis* / drug effects
  • Gene Expression Profiling
  • Glutathione / metabolism
  • Heme Oxygenase-1 / antagonists & inhibitors
  • Heme Oxygenase-1 / genetics*
  • Heme Oxygenase-1 / metabolism
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Iron Overload / complications
  • Lipid Peroxidation / drug effects
  • Male
  • Mice
  • Mice, Knockout
  • NADP / metabolism
  • Phenylenediamines / pharmacology
  • Protein Interaction Maps / drug effects
  • Protein Interaction Maps / genetics
  • Signal Transduction / drug effects
  • Up-Regulation* / drug effects
  • Up-Regulation* / genetics

Substances

  • Apolipoproteins E
  • Cyclohexylamines
  • Phenylenediamines
  • ferrostatin-1
  • NADP
  • Heme Oxygenase-1
  • Glutathione